Elevated homocysteine and C-reactive protein levels independently predict worsening prognosis after stroke in Chinese patients

Abstract

Increased plasma total homocysteine (tHcy) and high sensitivity C-reactive protein (hsCRP) levels are independent risk factors for cardiovascular disease. However, the predictive value of tHcy in combination with hsCRP in patients with stroke is not known. To determine the relationship between tHcy and hsCRP, we enrolled 291 patients with first-onset stroke (196 ischemic and 95 hemorrhagic). Plasma tHcy and hsCRP levels were measured and subsequent vascular events and deaths were determined over a 5-year period. Using the arbitrary cutoff for tHcy (<18 μmol/L and ≥18 μmol/L) and hsCRP (<1 mg/L, 1–3 mg/L and >3 mg/L), the patients were divided into 6 groups. Survival analysis showed that the probability of death or new vascular events during a 5-year follow-up increased according to tHcy and hsCRP levels (P<0.01). The relative risk (RR) of death or new vascular events was 4.67 (95% CI, 1.96 to 11.14, P=0.001) in patients with high tHcy (≥18 μmol/L) and hsCRP (>3 mg/L) compared with those with low tHcy (<18 μmol/L) and hsCRP (<1 mg/L). The increased tHcy level (≥18 μmol/L) combined with increased hsCRP level (>3 mg/L) was still significantly associated with the risk of death or new vascular events (RR, 4.10, 95% CI, 1.61 to 10.45, P=0.003) even when adjusted for other risk factors at inclusion. The combination of increased tHcy and hsCRP levels had a stronger predictive value than increased hsCRP alone or increased tHcy level alone. Further studies are required to evaluate the potential decrease in risks associated with lowering both Hcy and hsCRP levels in patients that present with both increased tHcy and hsCRP.

Keywords

homocysteine / C-reactive protein / inflammation / stroke

References

[1] HankeyG.J., EikelboomJ.W.. Homocysteine and vascular disease. Lancet, 1999, 354(9176): 407-413

[2] DurandP., ProstM., LoreauN., et al.. Impaired homocysteine metabolism and atherothrombotic disease. Lab Invest, 2001, 81(5): 645-672

[3] McCullyK.S.. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. The Am J of Pathol, 1969, 56(1): 111-128

[4] FaraciF.M., LentzS.R.. Hyperhomocysteinemia, oxidative stress, and cerebral vascular dysfunction. Stroke, 2004, 35(2): 345-347

[5] ToflerG.H., D’AgostinoR.B., JacquesP.F., et al.. Association between increased homocysteine levels and impaired fibrinolytic potential: potential mechanism for cardiovascular risk. Thromb Haemost, 2002, 88(5): 799-804

[6] ZhangC., CaiY., AdachiM.T., et al.. Homocysteine induces programmed cell death in human vascular endothelial cells through activation of the unfolded protein response. J Biol Chem, 2001, 276(38): 35867-35874

[7] BousheyC.J., BeresfordS.A., OmennG.S., et al.. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA, 1995, 274(13): 1049-1057

[8] Homocystein Studies Collaboration.. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA, 2002, 288(16): 2015-2022

[9] EikelboomJ.W., LonnE., GenestJ.Jr, et al.. Homocyst(e)ine and cardiovascular disease: A critical review of the epidemiologic evidence. Ann Intern Med, 1999, 131(5): 363-375

[10] KlerkM., VerhoefP., ClarkeR., et al.. MTHFR 677CT Polymorphism and risk of coronary heart disease: A meta-analysis. JAMA, 2002, 288(16): 2023-2031

[11] WaldD.S., LawM., MorrisJ.K.. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ, 2002, 325(7374): 1202-1206

[12] LibbyP.. Inflammation in atherosclerosis. Nature, 2002, 420(6917): 868-874

[13] BlakeG.J., RidkerP.M.. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med, 2002, 252(4): 283-294

[14] EngströmG., HedbladB., StavenowL., et al.. Fatality of future coronary events is related to inflammation-sensitive plasma proteins: A Population-based prospective cohort study. Circulation, 2004, 110(1): 27-31

[15] DaneshJ., WheelerJ.G., HirschfieldG.M., et al.. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med, 2004, 350(14): 1387-1397

[16] RostN.S., WolfP.A., KaseC.S., et al.. Plasma Concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: The framingham study. Stroke, 2001, 32(11): 2575-2579

[17] RidkerP.M., CushmanM., StampferM.J., et al.. Plasma concentration of c-reactive protein and risk of developing peripheral vascular disease. Circulation, 1998, 97(5): 425-428

[18] RidkerP.M., HennekensC.H., BuringJ.E., et al.. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med, 2000, 342(12): 836-843

[19] KoenigW., SundM., FrohlichM., et al.. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the monica (monitoring trends and determinants in cardiovascular disease) augsburg cohort study, 1984 to 1992. Circulation, 1999, 99(2): 237-242

[20] YoussefM.Y., MojiminiyiO.A., AbdellaN.A.. Plasma concentrations of C-reactive protein and total homocysteine in relation to the severity and risk factors for cerebrovascular disease. Transl Res, 2007, 150(3): 158-163

[21] BosM.J., van GoorM.L., KoudstaalP.J., et al.. Plasma homocysteine is a risk factor for recurrent vascular events in young patients with an ischaemic stroke or TIA. J Neurol, 2005, 252(3): 332-337

[22] LonnE., YusufS., ArnoldM.J., et al.. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med, 2006, 354(15): 1567-1577

[23] NORVIT Investigators.. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med, 2006, 354(15): 1578-1588

[24] Van GuelpenB., HultdinJ., JohanssonI., et al.. Folate, vitamin B12, and risk of ischemic and hemorrhagic stroke: A Prospective, nested case-referent study of plasma concentrations and dietary intake. Stroke, 2005, 36(7): 1426-1431

[25] ShaoJ., YanJ., YeH., et al.. Plasma homocysteine level associated with microalbuminuria in Chinese people. Chin J Internal Med, 2003, 42(4): 283-284

[26] HanssonG.K.. Inflammation, Atherosclerosis, and coronary artery disease. N Engl J Med, 2005, 352(16): 1685-1695

[27] RidkerP.M., CushmanM., StampferM.J., et al.. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med, 1997, 336(14): 973-979

[28] MegaJ.L., MorrowD.A., CannonC.P., et al.. Cholesterol, c-reactive protein, and cerebrovascular events following intensive and moderate statin therapy. J Thromb Thrombolysis, 2006, 22(1): 71-76

[29] RidkerP.M., CannonC.P., MorrowD., et al.. C-reactive protein levels and outcomes after statin therapy. N Engl J Med, 2005, 352(1): 20-28

[30] MuirK.W., WeirC.J., AlwanW., et al.. C-reactive protein and outcome after ischemic stroke. Stroke, 1999, 30(5): 981-985

[31] Di NapoliM., PapaF., BocolaV.. C-reactive protein in ischemic stroke: An independent prognostic factor. Stroke, 2001, 32(4): 917-924

[32] DusitanondP., EikelboomJ.W., HankeyG.J., et al.. Homocysteine-lowering treatment with folic acid, cobalamin, and pyridoxine does not reduce blood markers of inflammation, endothelial dysfunction, or hypercoagul-ability in patients with previous transient ischemic attack or stroke: A randomized substudy of the vitatops trial. Stroke, 2005, 36(1): 144-146